Pharmafile Logo
Pharmafocus logo
Advanced Search

NHS

Showing 15 posts of 1107 posts found.

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …

News
entresto

NICE gives green light to Novartis’s heart drug Entresto

April 27, 2016
Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients

NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …

News
abpi_reception

ABPI welcomes recommendations from NHS specialised services report

April 27, 2016
Research and Development, Sales and Marketing ABPI, NHS, NHS England, NICE, National Audit Office, report, specialised services

The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …

News
boots2

Sticking the boot in

April 18, 2016
Sales and Marketing Boots, Cost, Guardian, NHS, prescribing, scandal, unfair

A recent exposé has shone a light on the practices allegedly enforced at the nation’s largest pharmacy. So what exactly …

Feature
genome

UK’s genomics and personalised medicine expertise showcased at major international gathering

April 8, 2016
Manufacturing and Production, Research and Development 000 genomics project, 100, NHS, UK, expertise, genomics, international gathering, world leader

The UK’s expertise in genomics was showcased at a major international gathering to foster global collaboration in this burgeoning field. …

News
janssen_latest_logo_on_sign

Janssen-Cilag’s HIV treatment gets NHS backing

March 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial

Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV.  The company said following the …

News
abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016
Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …

News
humira_abbott_

Top 10 medicines issued in England by prescription cost in 2014-15

March 2, 2016
Research and Development, Sales and Marketing Cost, Humira, NHS, prescription

AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …

Feature
jeremy_hunt_appears_on_thye_bbcs_andrew_marr_show_february_7

UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision

February 8, 2016
Medical Communications, Sales and Marketing Jeremy Hunt, NHS

UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …

News
NHS NICE logo

NICE recommends six drugs in final guidance

January 27, 2016
Research and Development, Sales and Marketing NHS, NICE

NICE has published final recommendations approving drug treatments for ovarian cancer, prostate cancer, multiple myeloma, gastric cancer and idiopathic pulmonary …

News
NHS logo

UK Pfizer boss criticised for NHS conflict of interest

January 21, 2016
Erik Nordkamp, Keep Our NHS Public, King's College Hospitals NHS Trsut, NHS, Pfizer, conflict of interest, privitisation

Anti-privatisation campaigners have called on a London NHS hospital trust to revoke its decision to appoint the head of Pfizer …

News
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

News
Kadcyla

NICE says no to NHS funding for Kadcyla

December 16, 2015
Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …

News
Victoza

Novo Nordisk looks to HEOR data to back Victoza

November 11, 2015
Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness

A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …

News

NHS England reinstates treatments to Cancer Drugs Fund

November 4, 2015
Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NHS England

Five treatments in seven indications have been reinstated to Cancer Drugs Fund, as a result of negotiations between pharma companies …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026